Immunic, Inc. InvestorRoom

News Releases

July 1, 2021

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

- Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory Approval -
June 28, 2021

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July
June 10, 2021

Immunic, Inc. to Participate in Industry and Investor Conferences in June
June 1, 2021

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
May 6, 2021

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

- EMPhASIS Cohort 2 Interim Analysis Confirmed 30 mg Dose of IMU-838 as Most Appropriate for Planned Phase 3 Program in Relapsing-Remitting Multiple Sclerosis, Expected to Begin in the Second Half of 2021 -

Show per page